Neuromodulation for treatment-resistant depression

Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial...

Descripción completa

Detalles Bibliográficos
Autores principales: Holtzheimer, Paul E., Mayberg, Helen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506219/
https://www.ncbi.nlm.nih.gov/pubmed/23189091
http://dx.doi.org/10.3410/M4-22
_version_ 1782250869141536768
author Holtzheimer, Paul E.
Mayberg, Helen S.
author_facet Holtzheimer, Paul E.
Mayberg, Helen S.
author_sort Holtzheimer, Paul E.
collection PubMed
description Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. Of these, only two (transcranial magnetic stimulation and vagus nerve stimulation) currently have US Food and Drug Administration approval for the treatment of depression.
format Online
Article
Text
id pubmed-3506219
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Faculty of 1000 Ltd
record_format MEDLINE/PubMed
spelling pubmed-35062192012-11-27 Neuromodulation for treatment-resistant depression Holtzheimer, Paul E. Mayberg, Helen S. F1000 Med Rep Review Article Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. Of these, only two (transcranial magnetic stimulation and vagus nerve stimulation) currently have US Food and Drug Administration approval for the treatment of depression. Faculty of 1000 Ltd 2012-11-01 /pmc/articles/PMC3506219/ /pubmed/23189091 http://dx.doi.org/10.3410/M4-22 Text en © 2012 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Holtzheimer, Paul E.
Mayberg, Helen S.
Neuromodulation for treatment-resistant depression
title Neuromodulation for treatment-resistant depression
title_full Neuromodulation for treatment-resistant depression
title_fullStr Neuromodulation for treatment-resistant depression
title_full_unstemmed Neuromodulation for treatment-resistant depression
title_short Neuromodulation for treatment-resistant depression
title_sort neuromodulation for treatment-resistant depression
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506219/
https://www.ncbi.nlm.nih.gov/pubmed/23189091
http://dx.doi.org/10.3410/M4-22
work_keys_str_mv AT holtzheimerpaule neuromodulationfortreatmentresistantdepression
AT mayberghelens neuromodulationfortreatmentresistantdepression

Ejemplares similares